1. Home
  2. NYXH vs JCE Comparison

NYXH vs JCE Comparison

Compare NYXH & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NYXH
  • JCE
  • Stock Information
  • Founded
  • NYXH 2009
  • JCE 2007
  • Country
  • NYXH Belgium
  • JCE United States
  • Employees
  • NYXH N/A
  • JCE N/A
  • Industry
  • NYXH Medical/Dental Instruments
  • JCE Trusts Except Educational Religious and Charitable
  • Sector
  • NYXH Health Care
  • JCE Finance
  • Exchange
  • NYXH Nasdaq
  • JCE Nasdaq
  • Market Cap
  • NYXH 222.3M
  • JCE 235.3M
  • IPO Year
  • NYXH 2021
  • JCE N/A
  • Fundamental
  • Price
  • NYXH $7.65
  • JCE $15.03
  • Analyst Decision
  • NYXH Strong Buy
  • JCE
  • Analyst Count
  • NYXH 4
  • JCE 0
  • Target Price
  • NYXH $14.50
  • JCE N/A
  • AVG Volume (30 Days)
  • NYXH 151.3K
  • JCE 49.7K
  • Earning Date
  • NYXH 05-14-2025
  • JCE 01-01-0001
  • Dividend Yield
  • NYXH N/A
  • JCE 9.26%
  • EPS Growth
  • NYXH N/A
  • JCE N/A
  • EPS
  • NYXH N/A
  • JCE N/A
  • Revenue
  • NYXH $4,716,818.00
  • JCE N/A
  • Revenue This Year
  • NYXH $323.07
  • JCE N/A
  • Revenue Next Year
  • NYXH $204.30
  • JCE N/A
  • P/E Ratio
  • NYXH N/A
  • JCE N/A
  • Revenue Growth
  • NYXH N/A
  • JCE N/A
  • 52 Week Low
  • NYXH $5.55
  • JCE $11.64
  • 52 Week High
  • NYXH $11.87
  • JCE $14.28
  • Technical
  • Relative Strength Index (RSI)
  • NYXH 59.27
  • JCE 58.05
  • Support Level
  • NYXH $7.59
  • JCE $14.84
  • Resistance Level
  • NYXH $7.96
  • JCE $15.22
  • Average True Range (ATR)
  • NYXH 0.51
  • JCE 0.30
  • MACD
  • NYXH 0.16
  • JCE -0.02
  • Stochastic Oscillator
  • NYXH 67.22
  • JCE 60.17

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

Share on Social Networks: